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effect on the animals as the drugs must be administered by 
intraperitoneal injection. We can obtain the same inhibition of 
intimai thickening by introducing virally transduced smooth 
muscle cells overexpressing the natural inhibitor of MMPs, 
TIMP-1, without side effects. 
The current smooth muscle cell-based approach to gene 
transfer isnot likely to be of clinical utility because it is somewhat 
cumbersome and requires cell culture. Nevertheless, it provides 
proof of concept, which can then be exploited further when better 
direct gene transfer methods come on line. 
Conc lus ion  
We have been able to show that vascular smooth muscle cells 
can serve as useful vectors for transferring genes Of interest into 
blood vessels. Using smooth muscle cells transduced with replica- 
tion-defective r trovirus, we have been able to show that this 
approach is usefi,fl for systemic gene therapy, the development of
models of vascular disease, and local vascular pharmacology. 
Alexander W Clowes, MD 
University of Washington School of Medicine 
Seattle, Wash. 
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iNOS OVEREXPESSION TO MODIFY 
DISEASE STATES 
Normal human vascular physiology is dictated by an orchestrated 
array of counterregulatory mediators collaborating to maintain 
optimal tissue perfusion. One such mediator is endothelium- 
derived relaxing factor, first described in 1980, eventually identified 
as nitric oxide (NO) or a derivative thereof in 1987.1 This NO, 
originating from the endothelium from a resident constitutively 
expressed NO synthase nzyme (ecNOS or NOS-3), is a potent 
smooth muscle relaxant and is responsible for maintaining a state of 
resting vasodilation. NO has also been demonstrated to possess a
number of other vasoprotective properties. NO inhibits platelet 
adhesion and aggregation, and platelets themselves exhibit the 
capacity to synthesize an independent source of NO. In vitro data 
suggest that NO may inhibit vascular smooth muscle cell prolifera- 
tion through cell cycle arrest. Finally, NO may reduce leukocyte 
adherence and infiltration of the endothelial barrier. All of these 
functions may be essential defenses against vascular occlusive 
complications. 
The precise role of NO in the pathogenesis of vascular 
occlusive disorders uch as atheroscterosis and restenosis i still 
under intense investigation, but several studies hint at the relevance 
of NO depletion in the establishment and progression of these 
maladaptive states. An early event in the development of an 
atherosclerotic plaque is the accumulation of lipid-laden macro- 
phages in the intima with disturbance of the endothelium, z 
Endothefial NO synthesis may become impaired at these locations. 
In addition, oxidized lipoproteins have been demonstrated to
inactivate NO, thereby creating an environment that lacks NO. 
Diabetic patients are especially prone to an aggressive form of 
atherosclerosis. Their predilection may stem in part from progres- 
sive accumulation fglycosylated products that may also inactivate 
NO. Indeed, atherosclerotic arteries are less vasoresponsive to 
agonists uch as acetylcholine but are still able to vasodilate in 
response to authentic NO, suggesting reduced endogenous NO 
release. 
Vascular estenosis after therapeutic manipulation may also 
result from inadequate NO availability. Blood vessel injury is 
characterized by endothelial denudation with damage to the 
underlying smooth muscle cells. Exposed collagen and smooth 
muscle provide a prothrombogenic surface that invites leukocyte 
and platelet adhesion. A number of chemotactic and mitogenic 
factors are then released that facilitate cellular migration and 
proliferation, resulting in the creation of a neointima. It has been 
reported that the inducible NOS (iNOS or NOS-2) isoform is 
expressed transiently, beginning immediately and persisting for 1 to 
2 weeks, in arterial smooth muscle cells in response to balloon 
catheter-induced injury in rat carotid arteries? Unlike NOS-3, 
NOS-2 expression is detected in cells only after cytokine or 
mechanical perturbation, and the enzyme is several magnitudes 
more active in the absence ofagonist stimulation. NOS-2 induction 
as part of the vascular healing response may provide an alternate 
source of NO until endothelial integrity can be reestablished. 
Restenosis may derive from a defect in this response. 
Although the role of NO in the establishment of intimal 
hyperplasia s still unclear, the benefit of NO in preventing this 
response may be more evident. McNamara et al.4 reported a 39% 
reduction in intimai hyperplasia n injured rabbit carotid arteries 
with oral supplementation f the NOS substrata L-arginine. 
Similarly, Davies et ai.5 attenuated neointima formation by 47% and 
preserved vasoreactivity in vein grafts that were interposed in the 
carotid circulation with supplemental L-arginine alimentation. 
Finally, systemic administration of an NO donor 6 reduced the 
intimal thickness by 82% and accelerated reendothelialization n 
injured rat carotid arteries. These results, although indirect and in 
rodent models, strongly suggest he benefit of increased NO 
availability for the attenuation of the hyperplastic reaction to 
vascular injury. 
With these observations, the application of NO in the preven- 
tion ofrestenotic complications and even atherosclerosis may have 
therapeutic utility. To evaluate this hypothesis, a method of 
delivering a therapeutic dose of NO is necessary. One such option 
is systemic administration f NO donors. However, the potential 
for hypotensive side-effects i real. Also, the complexity of NO 
biology and all of its purported cytotoxic effects are incentives to 
localize NO exposure in a site-specific fashion. To achieve this, the 
best method may be gene transfer ofa NOS gene to sites of vascular 
injury at the time of therapeutic intervention, such as immediately 
after angioplasty. Indeed, vonder  Leyen et al. 7 examined the 
efficacy of liposome-mediated NOS-3 gene transfer at reducing 
intimal hyperplasia ina rat carotid artery injury model. The authors 
demonstrated reconstitution of NOS-3 activity in the injured 
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vessels to a level comparable to uninjured vessels. The NOS- 
3-transfected vessels showed a -70% reduction in neointimal 
thickness as compared with control injured carotid arteries. These 
results uggest NOS gene transfer may be beneficial in restenosis. 
A very important consideration that must be weighed is gene 
delivery efficiency by viral or nonviral methods. For clinical 
applications, vascular gene transfer must be accomplished with a 
minimal period of flow occlusion, especially in the coronary 
circulation, where minutes of occlusion can result in significant 
myocardial ischemia or infarction. With even the most efficient 
delivery system, that being the adenoviral vector, gene transfer 
efficiency will be low. For this reason, we hypothesize that gene 
delivery of the NOS-2 isoform may have some advantages over 
NOS-3. Low-efficiency transfer of this extremely active enzyme 
may still provide sufficient local concentrations of NO to achieve a
biologic effect. In addition, NOS-2 activity does not require 
calcium fluxes and will be maximal in the absence of agonist 
stimulation. 
Cytotoxicity from NOS-2 overexpression in native cells is a 
potential concern. Also, all NOS enzymes require the cofactor 
tetrahydrobiopterin (BH4). Certain cells lack constitutive biosyn- 
thesis of this cofactor and may be unable to support NOS-2 
activity, sBecause of these concerns, we evaluated the feasibility of 
NOS-2 gene transfer to vascular target cells. We constructed a 
retroviral vector carrying the human NOS-2 cDNA and neomycin 
phosphotransferase (DFGiNOS). 9 Sheep vascular endothelial cells 
infected with DFGiNOS and selected with neomycin supported 
mammal NOS-2 activity, producing over 20-fold more nitrite 
(NO2-) than cells infected with a control retrovirus ( 155.0 + 10.7 
nmol /mg protein/24 hr vs 5.5 _+ 1.1), without requirements for 
supplemental BH4. In contrast, rat vascular smooth muscle cells 
infected with DFGiNOS had no detectable NO 2- accumulation 
over control cells until BH 4 was provided (37.7 + 2.6 nmol /mg 
protein/24 hrwithout BH4,291.8 +_ 10.4withBH4),demonstrat- 
ing the insufficient cofactor levels in these cells. Interestingly, 
continuous expression of NOS-2 with NO synthesis did not result 
in significantly increased cytotoxicity as measured by Slchromium 
or lactate dehydrogenase release. 
We adapted an ex vivo organ culture system of arterial injury l° 
to assess the biologic efficacy of human NOS-2 gene transfer for 
preventing myointimal hyperplasia. Porcine femoral arterial seg- 
ments were infected with the DFGiNOS retrovirus or a control 
retrovirus 5 days after balloon-catheter injury and then cultured 
for another 9 days. By the fifth day after surgery, near maximal 
smooth muscle proliferation is occurring, 1° a favorable nviron- 
ment for retroviral infection. Vessels infected with DFGiNOS 
demonstrated a threefold increase in NO synthesis and a 15-fold 
increase in cGMP release over uninjured or control manipulated 
vessels. All early experiment had revealed a dependence ofNOS-2 
activity in these arterial segments on exogenous BH4, which was 
subsequently provided to all the experimental groups. Immuno- 
histochemical nalysis revealed only a 1% to 2% gene transfer 
efficiency, as would be expected with a retroviral vector. Balloon 
injury of the arterial segments resulted in a 53% increase in total 
myointimal thickness. Vessels expressing NOS-2, however, had a 
complete abrogation of this hyperplastic response and resembled 
uninjured controls; the administration fa NOS inhibitor eversed 
this protective ffect. 
Despite very low gene transfer efficiency, NOS 2 delivery to 
injured arterial segments successfully reduced intimal hyperplasia. 
The requirement for BH 4 is consistent with preferential delivery of 
the NOS-2 gene to the smooth muscle cells. Ongoing studies are 
aimed at determining whether the cofactor will be required for 
NOS-2 gene transfer in vivo and whether NOS-2 transfer will be of 
benefit in models of restenosis n large animals. 
Timothy R. Billiar, MD 
Edith Tzeng, MD 
Larry L. Shears II, MD 
University of Httsburgh Medical Center 
Pittsburgh, Pa. 
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D IRECT TRANSFER- -  
V IRAL  APPROACHES 
ADENOVIRAL VECTORS: PROMISES 
AND P ITFALLS  
Human adenovirus, representing over 40 different serotypes, are 
36 kb double-stranded DNA viruses. The molecular structure and 
regulation of this virus has been well studied over the years. The 
virus was first used in the 1980's for introducing foreign genes into 
cells. More recently, the E1 region of the virus that expresses 
transcriptional f ctors necessary to induce appropriate synthesis of 
the more than 70 viral proteins needed for viral replication has been 
removed, supplied in trans, and replaced with therapeutic gene 
sequences. Over the past 5 years, multiple studies performed by 
different laboratories have demonstrated that recombinant ade- 
